Business Context and Reporting Period
This Form 8-K was filed by Lantheus Holdings, Inc. on January 29, 2021, reporting a significant corporate event. The company is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol LNTH.
Key Financial Metrics
The filing discloses a specific transaction value but does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels for the reporting period.
- Transaction Proceeds: $18 million in cash (subject to working capital and other customary adjustments).
- Asset Sold: Radiopharmacy and PET manufacturing facility in San Juan, Puerto Rico.
- Buyer: PharmaLogic Holdings Corp.
Material Changes
The primary material change is the divestiture of the Puerto Rico facility. Concurrent with the sale, Lantheus entered into a long-term supply agreement to continue providing certain products to the buyer to meet a percentage of their commercial requirements. Proceeds from the sale are designated for use in Lantheus' core businesses and product pipeline.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or a discussion of specific risks and contingencies beyond the transaction details. The transaction was executed pursuant to a previously announced Securities Purchase Agreement.
Investor Verification Checklist
- Verify the final purchase price after working capital and customary adjustments are applied to the $18 million base.
- Review the specific terms and duration of the long-term supply agreement with PharmaLogic.
- Confirm the allocation of proceeds to specific core business initiatives or pipeline projects.
- Check subsequent filings for any impact on consolidated revenue or operating expenses resulting from the divestiture.